Nidogen-2 (NID2) is a Key Factor in Collagen Causing Poor Response to Immunotherapy in Melanoma

References

• Strashilov S, Yordanov A. Aetiology and pathogenesis of cutaneous melanoma: current concepts and advances. Int J Mol Sci. 2021;22(12):6395. doi:10.3390/ijms22126395
   PubMed Web of Science ®Google Scholar
• Cortez JL, Vasquez J, Wei ML. The impact of demographics, socioeconomics, and health care access on melanoma outcomes. J Am Acad Dermatol. 2021;84(6):1677–1683. doi:10.1016/j.jaad.2020.07.125
   PubMed Web of Science ®Google Scholar
• Cuevas LM, Daud AI. Immunotherapy for melanoma. Semin Cutan Med Surg. 2018;37(2):127–131. doi:10.12788/j.sder.2018.028
   PubMed Web of Science ®Google Scholar
• Luke JJ, Flaherty KT, Ribas A, et al. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol. 2017;14(8):463–482. doi:10.1038/nrclinonc.2017.43
   PubMed Web of Science ®Google Scholar
• Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189–2199. doi:10.1056/NEJMoa1406498
   PubMed Web of Science ®Google Scholar
• Willsmore ZN, Coumbe BGT, Crescioli S, et al. Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: treatment of melanoma and immune mechanisms of action. Eur J Immunol. 2021;51(3):544–556. doi:10.1002/eji.202048747
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122–133. doi:10.1056/NEJMoa1302369
   PubMed Web of Science ®Google Scholar
• Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res. 2013;19(19):5300–5309. doi:10.1158/1078-0432.CCR-13-0143
   PubMed Web of Science ®Google Scholar
• Tagliaferri L, Lancellotta V, Fionda B, et al. Immunotherapy and radiotherapy in melanoma: a multidisciplinary comprehensive review. Hum Vaccin Immunother. 2022;18(3):1903827. doi:10.1080/21645515.2021.1903827
   PubMed Web of Science ®Google Scholar
• Hamid O, Robert C, Daud A, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019;30(4):582–588. doi:10.1093/annonc/mdz011
   PubMed Web of Science ®Google Scholar
• Eggermont AMM, Blank CU, Mandalà M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, Phase 3 trial. Lancet Oncol. 2021;22(5):643–654. doi:10.1016/S1470-2045(21)00065-6
   PubMed Web of Science ®Google Scholar
• Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science. 2015;348(6230):74–80. doi:10.1126/science.aaa6204
   PubMed Web of Science ®Google Scholar
• Nakamura K, Smyth MJ. Myeloid immunosuppression and immune checkpoints in the tumor microenvironment. Cell Mol Immunol. 2020;17(1):1–12. doi:10.1038/s41423-019-0306-1
   PubMed Web of Science ®Google Scholar
• Marozzi M, Parnigoni A, Negri A, et al. Inflammation, extracellular matrix remodeling, and proteostasis in tumor microenvironment. Int J Mol Sci. 2021;22(15):8102. doi:10.3390/ijms22158102
   PubMed Web of Science ®Google Scholar
• Anderson NM, Simon MC. The tumor microenvironment. Curr Biol. 2020;30(16):R921–r925. doi:10.1016/j.cub.2020.06.081
   PubMed Web of Science ®Google Scholar
• Huang J, Zhang L, Wan D, et al. Extracellular matrix and its therapeutic potential for cancer treatment. Signal Transduct Target Ther. 2021;6(1):153. doi:10.1038/s41392-021-00544-0
   PubMed Web of Science ®Google Scholar
• Chakravarthy A, Khan L, Bensler NP, et al. TGF-β-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure. Nat Commun. 2018;9(1):4692. doi:10.1038/s41467-018-06654-8
   PubMed Web of Science ®Google Scholar
• Peng DH, Rodriguez BL, Diao L, et al. Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8(+) T cell exhaustion. Nat Commun. 2020;11(1):4520. doi:10.1038/s41467-020-18298-8
   PubMed Web of Science ®Google Scholar
• Theocharis AD, Skandalis SS, Gialeli C, et al. Extracellular matrix structure. Adv Drug Deliv Rev. 2016;97:4–27. doi:10.1016/j.addr.2015.11.001
   PubMed Web of Science ®Google Scholar
• Herrera J, Henke CA, Bitterman PB. Extracellular matrix as a driver of progressive fibrosis. J Clin Invest. 2018;128(1):45–53. doi:10.1172/JCI93557
   PubMed Web of Science ®Google Scholar
• Kaushik N, Kim S, Suh Y, et al. Proinvasive extracellular matrix remodeling for tumor progression. Arch Pharm Res. 2019;42(1):40–47. doi:10.1007/s12272-018-1097-0
   PubMed Web of Science ®Google Scholar
• Abyaneh HS, Regenold M, McKee TD, et al. Towards extracellular matrix normalization for improved treatment of solid tumors. Theranostics. 2020;10(4):1960–1980. doi:10.7150/thno.39995
   PubMed Web of Science ®Google Scholar
• Holmes DF, Lu Y, Starborg T, Kadler KE. Collagen fibril assembly and function. Curr Top Dev Biol. 2018;130:107–142.
   PubMed Web of Science ®Google Scholar
• Shi R, Zhang Z, Zhu A, et al. Targeting type I collagen for cancer treatment. Int J Cancer. 2022;151(5):665–683. doi:10.1002/ijc.33985
   PubMed Web of Science ®Google Scholar
• Zhang J, Liu J, Zhang H, et al. The role of network-forming collagens in cancer progression. Int J Cancer. 2022;151(6):833–842. doi:10.1002/ijc.34004
   PubMed Web of Science ®Google Scholar
• Chen Y, Yang S, Tavormina J, et al. Oncogenic collagen I homotrimers from cancer cells bind to α3β1 integrin and impact tumor microbiome and immunity to promote pancreatic cancer. Cancer Cell. 2022;40(8):818–834.e9. doi:10.1016/j.ccell.2022.06.011
   PubMed Web of Science ®Google Scholar
• Wang Z, Jensen MA, Zenklusen JC. A Practical Guide to The Cancer Genome Atlas (TCGA). Methods Mol Biol. 2016;1418:111–141.
   PubMedGoogle Scholar
• Yan K, Lu Y, Yan Z, et al. 9-gene signature correlated with CD8(+) T cell infiltration activated by IFN-γ: a biomarker of immune checkpoint therapy response in melanoma. Front Immunol. 2021;12:622563. doi:10.3389/fimmu.2021.622563
   PubMed Web of Science ®Google Scholar
• Zhang C, Li J, Guo Y, et al. Ese-3 inhibits the proliferation, migration, and invasion of HaCaT cells by downregulating PSIP1 and NUCKS1. Ann Clin Lab Sci. 2021;51(4):470–486.
   PubMed Web of Science ®Google Scholar
• Gao Y, Li Y, Niu X, et al. Identification and validation of prognostically relevant gene signature in melanoma. Biomed Res Int. 2020;2020:5323614. doi:10.1155/2020/5323614
   PubMed Web of Science ®Google Scholar
• Liu Y, Shou Y, Zhu R, et al. Construction and validation of a ferroptosis-related prognostic signature for melanoma based on single-cell RNA sequencing. Front Cell Dev Biol. 2022;10:818457. doi:10.3389/fcell.2022.818457
   PubMed Web of Science ®Google Scholar
• Wang X, Chai Z, Li Y, et al. Identification of potential biomarkers for anti-PD-1 therapy in melanoma by weighted correlation network analysis. Genes. 2020;11(4):435.
   PubMed Web of Science ®Google Scholar
• Li J, Smalley I, Chen Z, et al. Single-cell characterization of the cellular landscape of acral melanoma identifies novel targets for immunotherapy. Clin Cancer Res. 2022;28(10):2131–2146. doi:10.1158/1078-0432.CCR-21-3145
   PubMed Web of Science ®Google Scholar
• Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010;26(12):1572–1573. doi:10.1093/bioinformatics/btq170
   PubMed Web of Science ®Google Scholar
• Luo D, Liao S, Liu Y, et al. Holliday cross-recognition protein HJURP: association with the tumor microenvironment in hepatocellular carcinoma and with patient prognosis. Pathol Oncol Res. 2022;28:1610506. doi:10.3389/pore.2022.1610506
   PubMed Web of Science ®Google Scholar
• Chen X, Chen H, Yao H, et al. Turning up the heat on non-immunoreactive tumors: pyroptosis influences the tumor immune microenvironment in bladder cancer. Oncogene. 2021;40(45):6381–6393. doi:10.1038/s41388-021-02024-9
   PubMed Web of Science ®Google Scholar
• Gene Ontology Consortium. Gene Ontology Consortium: going forward. Nucleic Acids Res. 2015;43(Database issue):D1049–D1056. doi:10.1093/nar/gku1179
   PubMedGoogle Scholar
• Kanehisa M, Goto S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27–30. doi:10.1093/nar/28.1.27
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zhou B, Pache L, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10(1):1523. doi:10.1038/s41467-019-09234-6
   PubMed Web of Science ®Google Scholar
• Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 2013;14:7. doi:10.1186/1471-2105-14-7
   PubMed Web of Science ®Google Scholar
• Liberzon A, Birger C, Thorvaldsdóttir H, et al. The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1(6):417–425. doi:10.1016/j.cels.2015.12.004
   PubMed Web of Science ®Google Scholar
• Yang Y, Meyer K, Wind G, et al. Cloud products from the Earth Polychromatic Imaging Camera (EPIC): algorithms and initial evaluation. Atmos Meas Tech. 2019;12(3):2019–2031. doi:10.5194/amt-12-2019-2019
   PubMed Web of Science ®Google Scholar
• Wu J, Li L, Zhang H, et al. A risk model developed based on tumor microenvironment predicts overall survival and associates with tumor immunity of patients with lung adenocarcinoma. Oncogene. 2021;40(26):4413–4424. doi:10.1038/s41388-021-01853-y
   PubMed Web of Science ®Google Scholar
• Shen Y, Peng X, Shen C. Identification and validation of immune-related lncRNA prognostic signature for breast cancer. Genomics. 2020;112(3):2640–2646. doi:10.1016/j.ygeno.2020.02.015
   PubMed Web of Science ®Google Scholar
• Clough E, Barrett T. The gene expression omnibus database. Methods Mol Biol. 2016;1418:93–110.
   PubMedGoogle Scholar
• Yu X, Zhang Q, Zhang S, et al. Single-cell sequencing and establishment of an 8-gene prognostic model for pancreatic cancer patients. Front Oncol. 2022;12:1000447. doi:10.3389/fonc.2022.1000447
   PubMed Web of Science ®Google Scholar
• Kołat D, Kałuzińska Ż, Orzechowska M, et al. Functional genomics of AP-2α and AP-2γ in cancers: in silico study. BMC Med Genomics. 2020;13(1):174. doi:10.1186/s12920-020-00823-9
   PubMed Web of Science ®Google Scholar
• Song WM, Zhang B, Wang E. Multiscale embedded gene co-expression network analysis. PLoS Comput Biol. 2015;11(11):e1004574. doi:10.1371/journal.pcbi.1004574
   PubMed Web of Science ®Google Scholar
• Magaki S, Hojat SA, Wei B, et al. An introduction to the performance of immunohistochemistry. Methods Mol Biol. 2019;1897:289–298.
   PubMedGoogle Scholar
• Im K, Mareninov S, Diaz MF, Yong WH. An introduction to performing immunofluorescence staining. Methods Mol Biol. 2019;1897:299–311.
   PubMedGoogle Scholar
• Yang Y, Xiao M, Song Y, et al. H-score of 11β-hydroxylase and aldosterone synthase in the histopathological diagnosis of adrenocortical tumors. Endocrine. 2019;65(3):683–691. doi:10.1007/s12020-019-02022-8
   PubMed Web of Science ®Google Scholar
• World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–2194. doi:10.1001/jama.2013.281053
   PubMed Web of Science ®Google Scholar
• Jung H, Lee HH, Song KY, et al. Validation of the seventh edition of the American Joint Committee on Cancer TNM staging system for gastric cancer. Cancer. 2011;117(11):2371–2378. doi:10.1002/cncr.25778
   PubMed Web of Science ®Google Scholar
• Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47. doi:10.1093/nar/gkv007
   PubMed Web of Science ®Google Scholar
• Wu X, Sui Z, Zhang H, et al. Integrated analysis of lncRNA-mediated ceRNA network in lung adenocarcinoma. Front Oncol. 2020;10:554759. doi:10.3389/fonc.2020.554759
   PubMed Web of Science ®Google Scholar
• Riley RS, June CH, Langer R, et al. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019;18(3):175–196. doi:10.1038/s41573-018-0006-z
   PubMed Web of Science ®Google Scholar
• Herlyn M, Koprowski H. Melanoma antigens: immunological and biological characterization and clinical significance. Annu Rev Immunol. 1988;6:283–308. doi:10.1146/annurev.iy.06.040188.001435
   PubMed Web of Science ®Google Scholar
• Marzagalli M, Ebelt ND, Manuel ER. Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment. Semin Cancer Biol. 2019;59:236–250. doi:10.1016/j.semcancer.2019.08.002
   PubMed Web of Science ®Google Scholar
• Versluis JM, Reijers ILM, Rozeman EA, et al. Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma. Eur J Cancer. 2021;148:51–57. doi:10.1016/j.ejca.2021.02.012
   PubMed Web of Science ®Google Scholar
• Stachyra-Strawa P, Ciesielka M, Janiszewski M, et al. The role of immunotherapy and molecular‑targeted therapy in the treatment of melanoma (Review). Oncol Rep. 2021;46(2). doi:10.3892/or.2021.8109
   PubMed Web of Science ®Google Scholar
• Daud A. Current and emerging perspectives on immunotherapy for melanoma. Semin Oncol. 2015;42(Suppl 3):S3–S11. doi:10.1053/j.seminoncol.2015.10.003
   PubMedGoogle Scholar
• Bari S, Muzaffar J, Eroglu Z. Combination targeted and immune therapy in the treatment of advanced melanoma: a valid treatment option for patients? Ther Adv Med Oncol. 2022;14:17588359221090306. doi:10.1177/17588359221090306
   Web of Science ®Google Scholar
• Madden MZ, Rathmell JC. The complex integration of T-cell metabolism and immunotherapy. Cancer Discov. 2021;11(7):1636–1643. doi:10.1158/2159-8290.CD-20-0569
   PubMed Web of Science ®Google Scholar
• Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20(11):651–668. doi:10.1038/s41577-020-0306-5
   PubMed Web of Science ®Google Scholar
• Piersma B, Hayward MK, Weaver VM. Fibrosis and cancer: a strained relationship. Biochim Biophys Acta Rev Cancer. 2020;1873(2):188356. doi:10.1016/j.bbcan.2020.188356
   PubMed Web of Science ®Google Scholar
• Mohan V, Das A, Sagi I. Emerging roles of ECM remodeling processes in cancer. Semin Cancer Biol. 2020;62:192–200. doi:10.1016/j.semcancer.2019.09.004
   PubMed Web of Science ®Google Scholar
• Rømer AMA, Thorseth ML, Madsen DH. Immune modulatory properties of collagen in cancer. Front Immunol. 2021;12:791453. doi:10.3389/fimmu.2021.791453
   PubMed Web of Science ®Google Scholar
• Winkler J, Abisoye-Ogunniyan A, Metcalf KJ, et al. Concepts of extracellular matrix remodelling in tumour progression and metastasis. Nat Commun. 2020;11(1):5120. doi:10.1038/s41467-020-18794-x
   PubMed Web of Science ®Google Scholar
• Nissen NI, Karsdal M, Willumsen N. Collagens and cancer associated fibroblasts in the reactive stroma and its relation to cancer biology. J Exp Clin Cancer Res. 2019;38(1):115. doi:10.1186/s13046-019-1110-6
   PubMed Web of Science ®Google Scholar
• Li X, Li Z, Gu S, et al. A pan-cancer analysis of collagen VI family on prognosis, tumor microenvironment, and its potential therapeutic effect. BMC Bioinform. 2022;23(1):390. doi:10.1186/s12859-022-04951-0
   PubMed Web of Science ®Google Scholar
• Plaschka M, Benboubker V, Grimont M, et al. ZEB1 transcription factor promotes immune escape in melanoma. J Immunother Cancer. 2022;10(3):e003484. doi:10.1136/jitc-2021-003484
   PubMed Web of Science ®Google Scholar
• Shan Z, Wang W, Tong Y, et al. Genome-scale analysis identified NID2, SPARC, and MFAP2 as prognosis markers of overall survival in gastric cancer. Med Sci Monit. 2021;27:e929558. doi:10.12659/MSM.929558
   PubMed Web of Science ®Google Scholar
• Yu ZH, Wang Y-M, Jiang Y-Z, et al. NID2 can serve as a potential prognosis prediction biomarker and promotes the invasion and migration of gastric cancer. Pathol Res Pract. 2019;215(10):152553. doi:10.1016/j.prp.2019.152553
   PubMed Web of Science ®Google Scholar
• Fantony JJ, Longo TA, Gopalakrishna A, et al. Urinary NID2 and TWIST1 methylation to augment conventional urine cytology for the detection of bladder cancer. Cancer Biomark. 2017;18(4):381–387. doi:10.3233/CBM-160261
   PubMed Web of Science ®Google Scholar
• Roy B, Yuan L, Lee Y, et al. Fibroblast rejuvenation by mechanical reprogramming and redifferentiation. Proc Natl Acad Sci U S A. 2020;117(19):10131–10141. doi:10.1073/pnas.1911497117
   PubMed Web of Science ®Google Scholar
• Liu YT, Sun ZJ. Turning cold tumors into hot tumors by improving T-cell infiltration. Theranostics. 2021;11(11):5365–5386. doi:10.7150/thno.58390
   PubMed Web of Science ®Google Scholar
• Bonaventura P, Shekarian T, Alcazer V, et al. Cold tumors: a therapeutic challenge for immunotherapy. Front Immunol. 2019;10:168. doi:10.3389/fimmu.2019.00168
   PubMed Web of Science ®Google Scholar
• Lopez de Rodas M, Schalper KA. Tumour antigen-induced T cell exhaustion - The archenemy of immune-hot malignancies. Nat Rev Clin Oncol. 2021;18(12):749–750. doi:10.1038/s41571-021-00562-5
   PubMed Web of Science ®Google Scholar
• Fabian KP, Padget MR, Fujii R, et al. Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve. J Immunother Cancer. 2021;9(2):e001691.
   PubMed Web of Science ®Google Scholar
• Taefehshokr S, Parhizkar A, Hayati S, et al. Cancer immunotherapy: challenges and limitations. Pathol Res Pract. 2022;229:153723. doi:10.1016/j.prp.2021.153723
   PubMed Web of Science ®Google Scholar
• de Streel G, Bertrand C, Chalon N, et al. Selective inhibition of TGF-β1 produced by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer. Nat Commun. 2020;11(1):4545. doi:10.1038/s41467-020-17811-3
   PubMed Web of Science ®Google Scholar
• Lodyga M, Hinz B. TGF-β1 - A truly transforming growth factor in fibrosis and immunity. Semin Cell Dev Biol. 2020;101:123–139. doi:10.1016/j.semcdb.2019.12.010
   PubMed Web of Science ®Google Scholar
• Costa A, Kieffer Y, Scholer-Dahirel A, et al. Fibroblast heterogeneity and immunosuppressive environment in human breast cancer. Cancer Cell. 2018;33(3):463–479.e10. doi:10.1016/j.ccell.2018.01.011
   PubMed Web of Science ®Google Scholar